Tis is a platform technology not just limited to cancer treatment
Cancer is the focus at the moment, but the technology applies to a wide range of human diseases and has the potential to revolutionise the development of small molecules as drugs, it is a technology platform, not just a one compound one trick pony, watch this space.
Novogen Ltd (NRT – Australian Stock Exchange; NVGN – NASDAQ) was established in 1994 and generated a series of consumer products and drug discovery development pipelines based on isoflavonoid drug technology.
Novogen created the subsidiary, Marshall Edwards Inc (MEI) in 2002 and licensed to that company its intellectual property concerning isoflavonoid anti-cancer drugs.
In 2011, Novogen sold all of its intellectual property in relation to isoflavonoid drug to MEI which subsequently was renamed MEI Pharma Inc.
Novogen acquired Triaxial Pharmaceuticals Pty Ltd in Dec 2012. This company was established in 2009 by a number of scientists who had overseen the development of the core Novogen intellectual property in oncology drug discovery and development.
The goal of Triaxial was to develop a more efficient and effective way of discovering, designing and manufacturing new oncology products based on small molecules. To this end, Triaxial successfully developed a novel technology platform that generated significant improvements in:
The Novogen technology platform has the potential to revolutionise the development of small molecules as drugs for a wide range of human diseases, with cancer a particular focus.
Our immediate mission is to apply the technology platform to enable the design of small molecules that are able to achieve levels of potency, levels of bioavailability, and access to cancer tissues at levels not previously achievable.
By these drugs we hope to achieve the long-held aim of the medical profession ….. that of turning most forms of aggressive cancer into manageable diseases.
Novogen has by a core group of scientists with extensive experience in the biotechnology industry. The aim of that group of scientists is to conduct best-practise science that will make a meaningful difference to the lives of cancer patients, and that will reward shareholders that have put their faith in the Company and its technology.